Bcl‐2‐negative <i>IGH‐BCL2</i> translocation‐negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl‐2‐positive <i>IGH‐BCL2</i> translocation‐positive follicular lymphoma

Hamamoto, Yuichiro; Kukita, Yoji; Kitamura, Masanori; Kurashige, Masako; Masaie, Hiroaki; Fuji, Shigeo; Ishikawa, Jun; Honma, Keiichiro; Wakasa, T.; Hanamoto, Hitoshi; Hirokawa, Mitsuyoshi; Suzuki, Ayana; Morii, Eiichi; Nakatsuka, Shin-Ichi

doi:10.1111/his.14378

Cited by 5 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 41 A recent study with relatively few cases demonstrated the lack of chromatin modifying gene mutations but no special mutations were identified. 71 Similar cases have been reported in the ovary 39 and other extranodal sites; however, no genetic information is available. Nevertheless, all these extranodal lymphomas present with localized disease (stage IE), predominantly large cell cytology, often diffuse growth areas, diminished CD10 expression, and excellent prognosis compared with their t(14:18)-positive counterpart.…”

Section: Alternative Forms Of T(14;18)-negative Flmentioning

confidence: 60%

“… 35 Two of these features support systemic disease. Interestingly, the mutational profile of PCFCL is similar to other extranodal t(14;18)-negative FLs, 41 , 69 , 70 , 71 suggesting that inactivation of TNFRSF14 might play a role in the development of t(14;18)-negative lymphomas. The exact mechanism of TNFRSF14 mutations promoting FL lymphomagenesis remains to be elucidated.…”

Section: Alternative Forms Of T(14;18)-negative Flmentioning

confidence: 81%

“… Comparison of mutational landscape between t(14;18)-positive and t(14;18)-negative FL entities. Frequencies of recurrently mutated genes in 100 t(14;18)-positive FL ( BCL2 -pos FL), 17 31 duodenal-type FL (DTFL), 15 74 nodal t(14;18)-negative cases, 32 , 36 , 37 , 38 31 PCFCL, 34 , 35 10 lower female genital tract (LFGT) FL, 70 7 thyroid BCL2 -neg FL, 71 81 PTFL, 40 , 82 , 84 and 17 LBCL- IRF4. 91 Color gradient depicted per the percentage of mutated cases for each gene: dark red, 100%: dark green, 0%.…”

Section: Alternative Forms Of T(14;18)-negative Flmentioning

confidence: 99%

See 2 more Smart Citations

The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas

Quintanilla-Martı́nez

Salaverría

Weigert

2023

Blood Advances

View full text Add to dashboard Cite

Follicular lymphoma (FL) is a neoplasm derived from germinal center B cells, composed of centrocytes and centroblasts with at least a focal follicular growth pattern. The t(14;18) translocation together with epigenetic deregulation through recurrent genetic alterations are now recognized as the hallmark of FL. Nevertheless, FL is a heterogeneous disease clinically, morphologically, and biologically. The existence of FL lacking the t(14;18) chromosomal alteration highlights the complex pathogenesis of FL, and indicates that there are alternative pathogenetic mechanisms that can induce a neoplasm with follicular center B-cell phenotype. According to their clinical presentation t(14;18)-negative FL can be divided in three broad groups; nodal presentation, extranodal presentation, and those affecting predominantly children and young adults. Recent studies have shed some light into the genetic alterations of t(14;18)-negative FL. Within the group of t(14;18)-negative FL with nodal presentation, cases with STAT6 mutations are increasingly recognized as a distinctive molecular subgroup, often co-occurring with CREBBP and/or TNFRSF14 mutations. FL with BCL6 rearrangement shows clinicopathological similarities with the t(14;18)-positive counterpart. In contrast, t(14;18)-negative FL in extranodal sites are characterized mainly by TNFRSF14 mutations in the absence of chromatin modifying gene mutations. FL in children have unique molecular landscape when compared to adults. Pediatric-type follicular lymphoma (PTFL) is characterized by MAP2K1, TNFRSF14 and/or IRF8 mutations, whereas large B-cell lymphoma with IRF4 rearrangement is now recognized as a distinct entity different from PTFL. Ultimately, the better understanding of FL biology and heterogeneity should help to understand the clinical differences and help guiding patient management and treatment decisions.

show abstract

Section: Alternative Forms Of T(14;18)-negative Flmentioning

confidence: 60%

Section: Alternative Forms Of T(14;18)-negative Flmentioning

confidence: 81%

Section: Alternative Forms Of T(14;18)-negative Flmentioning

confidence: 99%

See 1 more Smart Citation

The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas

Quintanilla-Martı́nez

Salaverría

Weigert

2023

Blood Advances

View full text Add to dashboard Cite

show abstract

“…All tissue specimens were fixed in 10% formalin and neutral buffered solution, embedded in paraffin, cut into 4 μm thick serial sections, and used for both hematoxylin and eosin staining and immunohistochemical (IHC) staining. The latter was performed using the Roche BenchMark ULTRA IHC/ISH Staining Module (Ventana Medical Systems) according to the manufacturer’s instructions and a previous study 12. The primary antibodies used in this study, dilution ratios, and positive controls are listed in Table 2.…”

Section: Methodsmentioning

confidence: 99%

“…The latter was performed using the Roche BenchMark ULTRA IHC/ISH Staining Module (Ventana Medical Systems) according to the manufacturer's instructions and a previous study. 12 The primary antibodies used in this study, dilution ratios, and positive controls are listed in Table 2. The antibodies for MUC1 (H23), MUC5AC (MRQ- 19), and MUC6 (MRQ-20) used in our analysis were connected to the tandem-repeat domain.…”

Section: Hematoxylin and Eosin Staining And Immunohistochemistrymentioning

confidence: 99%

Aberrant MUC Immunohistochemical Expressions in Inflammatory Bowel Diseases

Hamamoto

Kawamura

Uchida

et al. 2022

Applied Immunohistochemistry &Amp; Molecular Morphology

Self Cite

View full text Add to dashboard Cite

Ulcerative colitis (UC) and Crohn disease (CD) are cryptogenic inflammatory bowel diseases that are suggestive of aberrant mucin (MUC) expression; however, their relationship remains unclear. Here, we examined aberrant MUC expression in intestinal samples from UC and CD patients in comparison to samples from patients with ischemic colitis and control groups. To study the expression of MUC1, MUC5AC, and MUC6 in different patient groups, we reviewed the slides stained with hematoxylin and eosin and performed immunohistochemistry. The results revealed that MUC1 was expressed more in the UC group and MUC6 in the CD group. No significant changes were observed in MUC expression in the ischemic colitis group. Overall, we demonstrated changes in MUC expression in UC and CD, which can help in the diagnosis and early clinical management of UC and CD.

show abstract